Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 333 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: insulin pre-treatment Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM, Acetaminophen test, Insulin-induced hypoglycemia, Exercise-induced hypoglycemia; Other
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus Type 1, Autoimmune Diabetes
Interventions: Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd); Drug · Biological
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 16 Years to 30 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes, Prediabetes
Interventions: Whole grain rice, Refined grain rice; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: DKA
Interventions: Insulin Glargine; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Hyperglycemia in Pregnant Diabetic Patients
Interventions: insulin pre-treatment; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Systemic Lupus Erythematosus
Interventions: PET/CT, Pioglitazone, Placebo; Radiation · Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus in Pregnancy, Diabetes, Gestational, Diabetes Mellitus, Type 2
Interventions: Glycemic Targets; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine at bedtime instead of NPH, NPH twice-daily; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions: Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide); Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 55 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Type2diabetes, Type 2 Diabetes Treated With Insulin
Interventions: Low-fat, vegan diet; Behavioral
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 85
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more

Conditions: Type 2 Diabetes
Interventions: Degludec, Glargine, Aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Spokane, Washington

Conditions: AMI
Interventions: Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glargine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions: Arginine hydrochloride, Sodium Chloride 0.9%; Drug
Lead sponsor: David K Carroll; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Type 1 Diabetes Mellitus
Interventions: Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: NNC0114-0006, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: La Jolla, California • Northridge, California • Aurora, Colorado + 10 more

Conditions: Euglycemia, Hypoglycemia, Hyperglycemia
Interventions: Exenatide 0.27 ng/kg/min, Exenatide 0.41 ng/kg/min, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Post Bariatric Hypoglycemia
Interventions: Avexitide, Placebo; Drug · Other
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Stanford, California • Aurora, Colorado • Jacksonville, Florida + 16 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Oral Insulin, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Years to 45 Years
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 13
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 10 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets; Procedure · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 68 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 9
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Sarcoma
Interventions: RG1507; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 22
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 15 more

Conditions: Diabetes Mellitus, Type 1
Interventions: insulin, human insulin inhalation powder (HIIP); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 25
States / cities: San Diego, California • Denver, Colorado • Hollywood, Florida + 22 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: Lancaster, California • Ventura, California • Walnut Creek, California + 9 more

Search by objective public record fields.

Glucagon Counterregulation in Type 1 Diabetes

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

Insulin Pre-treatment for Steroid-associated Hyperglycemia in Pregnant Diabetic Patients

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

Glycemic Targets for Pregnant Women With GDM and T2DM

Insulin Glargine Versus Twice-Daily NPH

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

The CARING Study: Creating and Restoring Health Through Nutrition Guidance

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Intravenous Exenatide (Byetta) During Surgery

Avexitide for Treatment of Post-Bariatric Hypoglycemia

Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

Efficacy of Islet After Kidney Transplantation

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.